Why the study?
Non-alcoholic fatty liver disease lacks approved therapies due to its complex pathophysiology, prompting interest in natural polysaccharides with pharmacological activities.
Do polysaccharides improve non-alcoholic fatty liver disease in preclinical models?
Do polysaccharides improve non-alcoholic fatty liver disease in preclinical models?
Natural polysaccharides demonstrate multi-target therapeutic potential against NAFLD in preclinical models, though structural complexity and quality control remain challenges for drug development.
Polysaccharides may target multiple NAFLD pathways; leaves open clinical translation pending human trials.
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and is a leading cause of cirrhosis and hepatocellular carcinoma. Due to its complex pathophysiology, there is currently no approved therapy. Polysaccharide, a kind of natural product, possesses a wide range of pharmacological activities. Numerous preclinical studies have confirmed that polysaccharides could interfere with the occurrence and development of NAFLD at multiple interrelated levels, such as improvement of glucose and lipid metabolism, antioxidation, anti-inflammation, and regulation of gut-liver axis, thus showing great potential as novel anti-NAFLD drugs. In this paper, we reviewed the polysaccharides with anti-NAFLD effect in recent years, and also systematically analyzed their possible pharmacological mechanisms.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: